Merkel cell carcinoma (MCC) is a rare malignant tumor of the skin. The development of MCC on non-sun-exposed skin is extremely rare, with few cases reported in the literature. The present authors aimed to highlight the characteristic features and treatment options of this tumor. The present authors present a 50-year-old man who developed MCC on the left gluteal region (nonsun-exposed skin). After surgery with clear margins, adjuvant radiotherapy was given. Three months after radiotherapy, lymphatic recurrence was observed and he was treated with chemotherapy. On follow-up, systemic metastases were found and palliative treatment was planned. Treatment options are surgery, radiotherapy (RT) and chemotherapy (ChT). For local disease, surgery is the mainstay of treatment and adjuvant RT is used in certain conditions. Surgery followed by RT AE ChT is suggested in patients with locally advanced disease. ChT is the first-line treatment for metastatic disease.
| INTRODUCTION
Merkel cell carcinoma (MCC) is a malignant neuroendocrine tumor of the skin which is typically located on sun exposed skin surfaces of elderly Caucasian men. The most common site of presentation is head and neck. MCC has a strong tendency to recur locally, regionally or systemically (Pectasides, Pectasides, & Economopoulos, 2006) . MCC commonly metastasizes to lung, liver, brain, bone, and skin (Peloschek et al., 2010) .
Treatment options are surgery, radiotherapy (RT) and chemotherapy (ChT). For local disease, surgery is the mainstay of treatment and adjuvant RT is used in certain conditions. Surgery followed by RT AE ChT is suggested in patients with locally advanced disease. ChT is the first-line treatment for metastatic disease.
To the best of our knowledge, this is the second described case of non-sun-exposed MCC which is located on gluteal region in a patient with kidney transplantation. Krej cí et al. has reported the first case of gluteal MCC in a patient with kidney transplantation (Krejci et al., 2010) . The aim of this report is to highlight the characteristic features and treatment options of this tumor.
| CASE REPORT
A 50-year-old man was admitted to plastic surgery department with a non-eroded, erythematous, growing skin lesion on the left gluteal region (Figure 1 ). Microscopic examination of the excisional biopsy showed a tumor composed of monotonous neoplastic cells with a high mitotic index (30-35 mitoses/10 hpf ). Tumor cells had round vesicular nuclei, scant cytoplasm, finely granular and dusty chromatin, and inconspicuous nucleoli. Immunohistochemical examination showed positive staining for cytokeratin-20 and low-molecular-weightcytokeratin in a perinuclear dot-like pattern, epithelial membrane antigen, CD56, synaptophysin, and chromogranin ( Figure 2 ). Thyroid transcription factor-1 and cytokeratin-7 expression was negative. Ki-67 was 70-80%. Based upon these findings, diagnosis of MCC was established. The tumor was 3,5 × 3 cm in diameter and 1,3 cm in depth. Lymphovascular invasion (LVI) was positive and the surgical margin was less than 1 mm.
With these pathological findings, the patient was referred to oncology clinic. Physical examination was normal. He had a history of hypertension, osteoporosis, thalassemia minor, and kidney transplantation due to chronic renal failure. Wide re-excision was suggested and performed to obtain safe surgical margin. Pelvic magnetic resonance imaging (MRI) and [ were detected. Palliative lymphatic RT followed by ChT/immunotherapy was planned. He rejected having immunotherapy. Currently, he is receiving RT and has been followed up for 15 months to date.
| DISCUSSION
MCC is a neuroendocrine skin tumor which was first described as trabecular carcinoma by (Toker, 1972) . It is a highly malignant tumor that develops from Merkel cells located in the basal layer of the epidermis.
MCC is found associated with many risk factors such as sunlight/ Ultraviolet light exposure, viral infections (HIV, Merkel Cell Polyomavirus), autoimmune diseases, immunosuppression, and history of organ transplantation (Schadendorf et al., 2017 (Becker, Schrama, & Houben, 2009 ).
MCC occurs mostly on sun-exposed skin surfaces. The most common location is head and neck, followed by upper extremities, lower extremities, and trunk. Recurrence rates are high even after wide resection of the primary tumor (local recurrence 27-60%,regional LN metastases 45-91%,distant metastases 18-52%) (Pectasides et al., 2006 ). Although extremely rare, non-sun-exposed MCC is a more malignant variant of MCC. Table 1 shows non-sun-exposed MCC from the English language literature. Marcoval et al. reported that patients with non-sun-exposed MCC have worse prognosis than those with sun-exposed MCC, and have a greater chance of death by MCC (Marcoval et al., 2014) .
Because of the high metastatic potential of this tumor, complete and accurate staging should be performed. MRI and CT can be used.
PET/CT is gaining importance in staging, treatment, and follow-up of MCC. It is an accurate tool with 90% sensitivity and 98% specificity (Treglia, Kakhki, Giovanella, & Sadeghi, 2013 (Paulson et al., 2013) . Retrospective series reported that adjuvant RT (50-60 Gy to the tumor bed) provided survival benefit (Lebbe et al., 2015) . In our case, all of the above-mentioned risk factors were present. Fifty-four Grays of radiotherapy was administered postoperatively to improve outcome.
For regional disease, surgery of the primary tumor and LN dissection should be performed. Adjuvant RT is recommended for patients with multiple lymph nodes and/or extracapsular extension.
Adjuvant ChT is not routinely advised, but can be used depending on clinical assessment. For metastatic disease, ChT is the first-line (Lebbe et al., 2015) . Immunotherapeutic agents such as avelumab, nivolumab, and pembrolizumab are promising for the treatment of metastatic MCC. There are no randomized trials comparing
ChT with immunotherapeutic agents but especially these three checkpoint immunotherapies provided similar response rates with ChT and ChT = chemotherapy, RT = radiotherapy, LN = lymph node, Tp = transplantation. they were associated with durable responses (Kaufman et al., 2016; Nghiem et al., 2016) Therefore avelumab, pembrolizumab, and nivolumab may be used as a first-line therapy in metastatic MCC patients.
Other than these treatment options, the use of phosphoinositide 3-kinase inhibitors, the mammalian target of rapamycin (mTOR) pathway inhibitors, apoptotic inhibitors, receptor tyrosine kinase inhibitors and octreotide were also reported in the treatment of MCC (Hughes et al., 2014) . Table 2 summerizes current suggested treatment options for MCC. Our patient refused surgery and received six courses of carboplatin/etoposide because of the lymphatic recurrence. Thereafter, regional and systemic recurrences were detected. Lymphatic RT followed by ChT/immunotherapy was planned. ChT will be given to the patient after RT, because he rejected having immunotherapy. Currently, he is receiving palliative RT.
| CONCLUSION
Although it is extremely rare, it must be kept in mind that nonsun-exposed MCC should be treated as aggressively as possible because of its highly malignant potential. Despite intensive therapies, recurrence rates are quite high and long-term follow-up is mandatory. More efficient treatments are needed to improve survival outcomes.
